Detalhe da pesquisa
1.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
N Engl J Med
; 389(2): 137-147, 2023 Jul 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37272535
2.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med
; 389(22): 2039-2051, 2023 Nov 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37870976
3.
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Mol Cancer
; 23(1): 115, 2024 May 30.
Artigo
Inglês
| MEDLINE | ID: mdl-38811992
4.
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden.
Psychosom Med
; 86(4): 334-341, 2024 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38436657
5.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Future Oncol
; 2024 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38357801
6.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(18): 1711-1723, 2020 10 29.
Artigo
Inglês
| MEDLINE | ID: mdl-32955177
7.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
N Engl J Med
; 383(9): 825-835, 2020 08 27.
Artigo
Inglês
| MEDLINE | ID: mdl-32846061
8.
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.
Future Oncol
; 18(28): 3133-3141, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35950566
9.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 22(1): 51-65, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33285097
10.
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(12): 1441-1464, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34902832
11.
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Future Oncol
; 17(35): 4827-4835, 2021 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34723634
12.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet
; 394(10212): 1929-1939, 2019 11 23.
Artigo
Inglês
| MEDLINE | ID: mdl-31590988
13.
Targeted Therapy for Non-Small Cell Lung Cancer.
Semin Respir Crit Care Med
; 41(3): 409-434, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32450595
14.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
Inglês
| MEDLINE | ID: mdl-25923550
15.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
; 372(21): 2018-28, 2015 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-25891174
16.
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.
Radiology
; 287(1): 326-332, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29232184
17.
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Invest New Drugs
; 36(4): 629-637, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29196957
18.
PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.
BMC Nephrol
; 19(1): 210, 2018 08 20.
Artigo
Inglês
| MEDLINE | ID: mdl-30126374
19.
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Lancet Oncol
; 18(7): 895-903, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28551359
20.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol
; 18(1): 31-41, 2017 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27932067